Journal of Clinical & Experimental Pharmacology

Drug delivery system targeting advanced hepatocellular carcinoma

8^th World Congress on Pharmacology and Toxicology

July 24-25, 2017 Melbourne, Australia

Xue Zhang, Congcong Lin, Zhijun Yang and Hong Qi Zhang

Hong Kong Baptist University, China

Scientific Tracks Abstracts: Clin Exp Pharmacol

Abstract:

Hepatocellular Carcinoma (HCC) has a fairly high morbidity and is notoriously difficult to treat due to long latent period before detection, multidrug resistance and severe drug-related adverse effects from chemotherapy. Targeted Drug Delivery Systems (DDS) that can selectively deliver therapeutic drugs into tumor sites have demonstrated a great potential in cancer treatment, which could be utilized to resolve the limitations of conventional chemotherapy. Numerous preclinical studies of DDS have been published, but targeted DDS for HCC has yet to be made for practical clinical use. Since rational targeted DDS design should take cancer specific properties into consideration, we have reviewed the biological and physicochemical properties of HCC extensively to provide a comprehensive understanding on HCC and recent DDS studies on HCC, aiming to find some potential targeted DDSs for HCC treatment and a meaningful platform for further development of HCC treatments.

Biography :

Xue Zhang has obtained his Master of Surgery and PhD degrees from University of New South Wales, Australia, and has been working in School of Chinese Medicine, Hong Kong Baptist University since 1999, as a Department Director from 2012 to 2015. He has broad research interest and connections, but in recent year more dedicated to stem cell research and drug delivery for cancer treatment on supervising a PhD student.

Email: hqzhang@hkbu.edu.hk